232 related articles for article (PubMed ID: 33659999)
1. Identified lung adenocarcinoma metabolic phenotypes and their association with tumor immune microenvironment.
Wu XN; Su D; Mei YD; Xu MQ; Zhang H; Wang ZY; Li LL; Peng L; Jiang JY; Yang JY; Li DJ; Cao H; Xia ZW; Zeng WJ; Cheng Q; Zhang N
Cancer Immunol Immunother; 2021 Oct; 70(10):2835-2850. PubMed ID: 33659999
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis.
Bi G; Chen Z; Yang X; Liang J; Hu Z; Bian Y; Sui Q; Li R; Zhan C; Fan H
Cancer Immunol Immunother; 2020 Jul; 69(7):1293-1305. PubMed ID: 32189030
[TBL] [Abstract][Full Text] [Related]
3. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
4. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive molecular analyses of cuproptosis-related genes with regard to prognosis, immune landscape, and response to immune checkpoint blockers in lung adenocarcinoma.
Li R; Tong R; Zhang JL; Zhang Z; Deng M; Hou G
J Cancer Res Clin Oncol; 2024 May; 150(5):246. PubMed ID: 38722401
[TBL] [Abstract][Full Text] [Related]
6. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
[TBL] [Abstract][Full Text] [Related]
7. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
Guo L; Li X; Liu R; Chen Y; Ren C; Du S
Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
[TBL] [Abstract][Full Text] [Related]
9.
Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
Front Immunol; 2021; 12():677169. PubMed ID: 34354701
[TBL] [Abstract][Full Text] [Related]
10. Machine learning reveals two heterogeneous subtypes to assist immune therapy based on lipid metabolism in lung adenocarcinoma.
Gu X; Wei S; Li Z; Xu H
Front Immunol; 2022; 13():1022149. PubMed ID: 36238302
[TBL] [Abstract][Full Text] [Related]
11. Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma.
Liu J; Shen H; Gu W; Zheng H; Wang Y; Ma G; Du J
Front Immunol; 2022; 13():960738. PubMed ID: 36032135
[TBL] [Abstract][Full Text] [Related]
12. Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures.
Wu Q; Wang L; Wei H; Li B; Yang J; Wang Z; Xu J; Zhou YL; Zhang B
Int Immunopharmacol; 2020 Jun; 83():106477. PubMed ID: 32278127
[TBL] [Abstract][Full Text] [Related]
13. Heat shock factor 5 correlated with immune infiltration serves as a prognostic biomarker in lung adenocarcinoma.
Aizemaiti R; Wu Z; Tang J; Yan H; Lv X
Int J Med Sci; 2021; 18(2):448-458. PubMed ID: 33390814
[TBL] [Abstract][Full Text] [Related]
14. Multi-omics analysis of m
Wu X; Bai Z
Sci Rep; 2021 Oct; 11(1):20921. PubMed ID: 34686691
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
Wang W; Ren S; Wang Z; Zhang C; Huang J
Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
[TBL] [Abstract][Full Text] [Related]
16. The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma.
Li X; Dai Z; Wu X; Zhang N; Zhang H; Wang Z; Zhang X; Liang X; Luo P; Zhang J; Liu Z; Zhou Y; Cheng Q; Chang R
Front Immunol; 2022; 13():749241. PubMed ID: 35529878
[TBL] [Abstract][Full Text] [Related]
17. Establishment and validation of an eight-gene metabolic-related prognostic signature model for lung adenocarcinoma.
Ma W; Liang J; Liu J; Tian D; Chen Z
Aging (Albany NY); 2021 Feb; 13(6):8688-8705. PubMed ID: 33619235
[TBL] [Abstract][Full Text] [Related]
18. Molecular subtypes based on ferroptosis-related genes and tumor microenvironment infiltration characterization in lung adenocarcinoma.
Zhang W; Yao S; Huang H; Zhou H; Zhou H; Wei Q; Bian T; Sun H; Li X; Zhang J; Liu Y
Oncoimmunology; 2021; 10(1):1959977. PubMed ID: 34527427
[TBL] [Abstract][Full Text] [Related]
19. Identification of a TGF-β signaling-related gene signature for prediction of immunotherapy and targeted therapy for lung adenocarcinoma.
Yu Q; Zhao L; Yan XX; Li Y; Chen XY; Hu XH; Bu Q; Lv XP
World J Surg Oncol; 2022 Jun; 20(1):183. PubMed ID: 35668494
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]